Scholars Central

Conference abstractPublished 20 Nov 2013

Gene expression profiling and p53 and Myc oncogenic pathways as biomarker and drug target in hematologic malignancies

Authors: Ken H. Young

The University of Texas MD Anderson Cancer Center, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Diffuse large B-cell lymphoma (DLBCL) is the most common and devastating form of non-Hodgkin lymphoma (NHL) in the world. The incidence of NHL and DLBCL, ranked fifth of all cancer types in the United States, has increased by at least 100% over the last twenty years. Majority of patients diagnosed with DLBCL are elderly (65 year-old) with poor survival. The objective of this study is to determine the impact of specific p53 and Myc genetic aberrations and altered genetic/phenotypic expression patterns in lymphoma patients. The present project is the initiation of a large-scale clinical attempt in our group to identify new molecular links between p53 or Myc genetic aberrations and clinical. Specifically, we analyze to address: (1) the distribution profile of p53 and Myc genetic aberrations (mutation and deletion) in a large cohort of 900 DLBCL patients; (2) whether any or subsets of p53 and Myc aberrations have predictive value for clinical outcome in DLBCL; (3) whether genetic subtypes of DLBCL with different clinical outcome will exhibit unique structural profiles of p53 and Myc gene aberrations; (4) the location of critical mutations on the p53 and Myc molecule that play significant roles as prognostic indicators in DLBCL by structural analysis, and finally (5) the correlation of the gene expression profiling and genetic data with the results obtained from functional study to determine if there are unique gene expression alterations associated with specific candidate genes or unique genetic pathway. The general approaches delineated in this study are used to expand our study for additional molecular targets, in the same signaling pathway that are responsible for cancer patients. We build a prognostic model combining both the genetic information obtained in this study and associated clinical data. The findings provide insight into the functional consequence of the p53 and Myc genetic lesions and targeted treatment regimens.

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Cell Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Science & Therapy
  • SubjectBiology
  • BylineArticles whose byline prints “Ken H. Young”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels